Compare Novartis AG (NVS) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Quantum Computing Inc — how do they compare? Novartis AG trades at $142.86 (market cap $268.57B), while Quantum Computing Inc trades at $7.55 (market cap $1.69B). The key difference: Novartis AG is far larger — about 158.9× Quantum Computing Inc's market cap, and Novartis AG pays a 3.31% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Quantum Computing Inc for 25 Days on average.
| NVS | QUBT | |
|---|---|---|
Market Cap | $268.57B | $1.69B |
Volume | 1,532,573 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $168.62 | $21.78 |
52-Week Low | $121.80 | $6.31 |
Typical Hold Time | 82 Days | 25 Days |
Enterprise Value | $309.89B | $753.24M |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Quantum Computing Inc. (QUBT) trades at $7.62, down 3.05% today, with a bearish technical signal despite bullish oscillators. The company shows explosive revenue growth from $682K in 2025 to $10M in 2026 but remains deeply unprofitable with a -152.45% net income margin. Recent developments include the Dirac-3S quantum system announcement and a $42.5M backlog, though rising expenses and cash burn persist.
Analysts maintain a bullish consensus with a $17.33 price target (75% buy ratings), seeing potential in QUBT's quantum technology expansion. However, significant execution risks, continued losses, and high valuation (P/S 157.36) create substantial downside potential if commercialization timelines slip or funding needs increase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
